Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NLSPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1687887 |
Shares Outstanding - | Shares Floating 1687887 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG is a Swiss biopharmaceutical company founded in 2015, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.
Core Business Areas
- Lead Product Candidate - Quilienceu00ae: Quilienceu00ae (mazindol ER) is a proprietary extended-release formulation of mazindol, a norepinephrine-dopamine reuptake inhibitor (NDRI). It is in development for the treatment of narcolepsy and potentially other neurological disorders.
- Anorexants (Under Development): NLS Pharmaceutics AG is also researching and developing other anorexant-based therapies for various indications. These other anorexant-based therapies are not yet on the market.
Leadership and Structure
The leadership team comprises experienced professionals in drug development and commercialization. The organizational structure is typical of a clinical-stage biopharmaceutical company, with functional departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Quilienceu00ae: Quilienceu00ae (mazindol ER) is the companyu2019s lead product candidate. Currently in clinical development for narcolepsy, market share is non-existent because it has not been approved by the FDA. Competitors include medications like Sunosi, Wakix, Xyrem, and Xywav.
Market Dynamics
Industry Overview
The pharmaceutical industry for central nervous system (CNS) disorders is large and growing, driven by aging populations and increased awareness of mental health conditions. However, there are very high regulatory hurdles and strict product testing needed to be profitable.
Positioning
NLS Pharmaceutics AG focuses on rare and complex CNS disorders with unmet medical needs, which allows it to potentially gain orphan drug designations and streamlined regulatory pathways. They are still in the development stage.
Total Addressable Market (TAM)
The total addressable market for narcolepsy treatments is estimated to be in the billions of USD. NLS Pharmaceutics AG is positioning itself to capture a portion of this market with Quilienceu00ae.
Upturn SWOT Analysis
Strengths
- Proprietary extended-release formulation of mazindol
- Focus on rare CNS disorders with unmet needs
- Experienced leadership team
- Potential for orphan drug designation
Weaknesses
- Limited product pipeline
- High dependence on successful clinical trials
- No currently marketed products
- Reliance on external funding
Opportunities
- Expansion of Quilienceu00ae into new indications
- Potential for partnerships and collaborations
- Market growth in CNS disorder treatments
- Positive clinical trial results for Quilienceu00ae
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and new treatments
- Funding challenges
Competitors and Market Share
Key Competitors
- JAZZ
- AVXL
- GWPH
Competitive Landscape
NLS Pharmaceutics AG faces significant competition from established pharmaceutical companies. Success hinges on demonstrating superior efficacy and safety with Quilienceu00ae.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the lack of marketed products.
Future Projections: Future growth is contingent on the successful development and commercialization of Quilienceu00ae and other pipeline products. Analyst projections vary widely, depending on trial outcomes.
Recent Initiatives: Recent initiatives include advancing Quilienceu00ae through clinical trials, securing funding, and exploring partnerships.
Summary
NLS Pharmaceutics AG is a high-risk, high-reward clinical-stage biopharmaceutical company. The company's success hinges on the clinical trial outcomes and regulatory approval of Quilienceu00ae. Positive results could lead to significant market opportunities, while failures could negatively impact its future prospects. They currently do not have any product on the market but are focusing on clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), investor presentations, press releases, analyst reports.
- Financial Modeling Prep API
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. The information provided is based on available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.